bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure 2 from SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
Authors: Tang Sai-Wen , Bilke Sven , Cao Liang , Murai Junko , Sousa Fabricio G. , Yamade Mihoko , Rajapakse Vinodh , Varma Sudhir , Helman Lee J. , Khan Javed , Meltzer Paul S. , Pommier Yves
Published: April 2023

Supplementary figure 2. Scatterplots showing correlations between FLI1 expression (x axis, Log2 normalized intensity) and ETS1 expression (y axis, Log2 normalized intensity) in breast and prostate cancers. n, number of samples; r, correlation coefficient.
Supplemental Tables 1 and 2 from Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group
Authors: Vo Kieuhoa T. , Edwards Jeremy V. , Epling C. Lorrie , Sinclair Elizabeth , Hawkins Douglas S. , Grier Holcombe E. , Janeway Katherine A. , Barnette Phillip , McIlvaine Elizabeth , Krailo Mark D. , Barkauskas Donald A. , Matthay Katherine K. , Womer Richard B. , Gorlick Richard G. , Lessnick Stephen L. , Mackall Crystal L. , DuBois Steven G.
Published: April 2023

Supplemental Table 1. Association of clinical features with BM micrometastatic cell burden (CD99+CD45- percent) in flow cytometry cohort. Supplemental Table 2. Total CD99+CD45- percent burden in Ewing sarcoma patients with clinically evident BM metastasis (N=6).
Supplemental Tables 1 - 3 and Figures 1 - 2 from Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer
Authors: Yu Kenneth H. , Ricigliano Mark , Hidalgo Manuel , Abou-Alfa Ghassan K. , Lowery Maeve A. , Saltz Leonard B. , Crotty Joseph F. , Gary Kristen , Cooper Brandon , Lapidus Rena , Sadowska Mariola , O'Reilly Eileen M.
Published: April 2023

Supplementary Table 1: List of genes used for PGx modeling Supplementary Table 2: Correlation of PGx model prediction in tumor tissue to CTICs, soft tissue sarcoma. Supplementary Table 3. Normalized Enrichment Scores for chemotherapeutic agents modeled in three pancreatic cancer derived xenografts, referenced in (Figure 2). Supplementary Figure 1. Correlation of PGx model prediction in tumor tissue to CTICs, soft tissue sarcoma. Supplementary Figure 2. Correlation of Treatment Score to (A) PFS and (B) OS.
Supplementary Methods from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Authors: Li Xinqun , Truty Mark A. , Kang Ya'an , Chopin-Laly Xavier , Zhang Ran , Roife David , Chatterjee Deyali , Lin E. , Thomas Ryan M. , Wang Huamin , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Clinical Correlation Studies, Tissue Microarray and Statistical Analysis.
Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Authors: Bill Kate Lynn J. , Garnett Jeannine , Meaux Isabelle , Ma XiaoYen , Creighton Chad J. , Bolshakov Svetlana , Barriere Cedric , Debussche Laurent , Lazar Alexander J. , Prudner Bethany C. , Casadei Lucia , Braggio Danielle , Lopez Gonzalo , Zewdu Abbie , Bid Hemant , Lev Dina , Pollock Raphael E.
Published: April 2023

Supplementary Data from SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Supplementary Figure 1 from Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα–Driven Leukemia
Authors: Coltella Nadia , Valsecchi Roberta , Ponente Manfredi , Ponzoni Maurilio , Bernardi Rosa
Published: April 2023

Supplementary Figure 1: EZN-2208 does not impair cell migration and colony formation in U937-MT control cells
Supplementary Figure 2 from Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
Authors: Kim Hyung Suk , Jeong Chang Wook , Kwak Cheol , Kim Hyeon Hoe , Ku Ja Hyeon
Published: April 2023

Funnel plots of the publication bias tests. Each point represents a separate study for the indicated association. The vertical line represents the mean effect size. (A) Radical cystectomy alone versus the methotrexate/vinblastine/Adriamycin®/cisplatin regimen (MVAC) of neo-adjuvant chemotherapy (NACH). (B) Radical cystectomy alone versus gemcitabine/cisplatin (GC) NACH. (C) Methotrexate/vinblastine/Adriamycin®/cisplatin MVAC NACH versus GC NACH.
Supplementary Table S1. Results of FGFR1 protein expression and FGFR1 gene copy-numbers in HPV-positive and HPV-negative head and neck squamous cell carcinoma. from FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma
Authors: Koole Koos , Brunen Diede , van Kempen Pauline M.W. , Noorlag Rob , de Bree Remco , Lieftink Cor , van Es Robert J.J. , Bernards René , Willems Stefan M.
Published: April 2023

FGFR1 protein expression was determined by immunohistochemistry on tissue microarray slides containing 443 head and neck squamous cell carcinoma. FGFR1 gene copy-numbers were determined by fluorescence in situ hybridization with FGFR1 FISH probes. FGFR1: fibroblast growth factor receptor 1, HPV: human papillomavirus
Supplementary Table 2 from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Table 2. Surgical patient description 2
Supplementary Figure 4 from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Figure 4. Comparison of IL-8 serum concentrations with the serum concentration of IL-6 and c-reactive protein (CRP) in available samples from 14 melanoma and 19 RCC patients from Figure 2A. (**, p<0.01; ***, p<0.001; ****, p<0.0001).
Supplementary Figure 3 from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Figure 3. Quantitative RT-PCR analyses of the mRNA encoding IL-8 in malignant cells from the biopsy of three melanoma patients. The serum IL-8 levels at the time of the biopsy from each patient is provided under the graph.
Supplementary Figure 1A from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Figure 1A. Quantitative RTPCR analysis of the mRNA encoding IL-8 in the human colorectal cancer (HT29) and melanoma (ICNI and UMBY) cell lines subjected to normoxia or 1% O2 as indicated.
Table S1 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Table S1. Cell line characteristics
Supplemental Figure 2 from BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Authors: Olow Aleksandra , Mueller Sabine , Yang Xiaodong , Hashizume Rintaro , Meyerowitz Justin , Weiss William , Resnick Adam C. , Waanders Angela J. , Stalpers Lukas J.A. , Berger Mitchel S. , Gupta Nalin , James C. David , Petritsch Claudia K. , Haas-Kogan Daphne A.
Published: April 2023

In vitro response to co-inhibition of MAPK and mTOR pathways in BRAFV600E mutated AM-38 glioma cells.
Suppl. Fig. 5 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

ADAM17 inhibition sensitizes irradiated NSCLC cells for senescence.
Suppl. Fig. 1 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

Ionizing Radiation (IR) induces the secretion of multiple ADAM substrates.
Supplementary Figure 3 from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Performance of the radiation sensitivity signature with the previously published radiation sensitivity signature in the training dataset.
Supplementary table 7 from Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Authors: Lopez Sandra M. , Agoulnik Alexander I. , Zhang Manqi , Peterson Leif E. , Suarez Egla , Gandarillas Gregory A. , Frolov Anna , Li Rile , Rajapakshe Kimal , Coarfa Christian , Ittmann Michael M. , Weigel Nancy L. , Agoulnik Irina U.
Published: April 2023

Correlation analysis between NCOR1 and NCOR2 expression and AR transcriptional output
Supplementary Tables from Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic Cancer
Authors: Chan Alison , Prassas Ioannis , Dimitromanolakis Apostolos , Brand Randall E. , Serra Stefano , Diamandis Eleftherios P. , Blasutig Ivan M.
Published: April 2023

Supplementary Tables. Table S1: STARD checklist for reporting of studies of diagnostic accuracy. Table S2: QC Values and statistics for the ELISAs. Table S3: Statistics of each markers in healthy, benign and cancer patients. Table S4: Model fit diagnostics for non-log2 and log2-transformed marker models comparing Benign vs. all PDAC groups. Table S5: Logistic regression coefficients and significance p-values for 3 multi-parametric models. Table S6: Logistic regression model comparison in the training set comparing Benign vs. all PDAC (Likelihood Ratio Test). Table S7: Association of markers with age and gender in the healthy and benign groups.
Supplemental Fig.3 from miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Authors: Yang Yijun , Li Fei , Saha Manujendra N. , Abdi Jahangir , Qiu Lugui , Chang Hong
Published: April 2023

Supplemental Fig.3. The effect of miR137/197 suppression using synthetic miRNA inhibitor oligonucleotides on the viability of MM cells.
Supplementary Table 1 from Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Authors: Chua Jia Xin , Vankemmelbeke Mireille , McIntosh Richard S. , Clarke Philip A. , Moss Robert , Parsons Tina , Spendlove Ian , Zaitoun Abid M. , Madhusudan Srinivasan , Durrant Lindy G.
Published: April 2023

Supplementary Table 1. containing kinetic and equilibrium binding parameters for FG88.2 and FG88.7
Supplementary Information, Supplementary References, Supplementary Figures 1-2, Supplementary Tables 1-10 from Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma
Authors: Sohn Bo Hwa , Shim Jae-Jun , Kim Sang-Bae , Jang Kyu Yun , Kim Soo Mi , Kim Ji Hoon , Hwang Jun Eul , Jang Hee-Jin , Lee Hyun-Sung , Kim Sang-Cheol , Jeong Woojin , Kim Sung Soo , Park Eun Sung , Heo Jeonghoon , Kim Yoon Jun , Kim Dae-Ghon , Leem Sun-Hee , Kaseb Ahmed , Hassan Manal M. , Cha Minse , Chu In-Sun , Johnson Randy L. , Park Yun-Yong , Lee Ju-Seog
Published: April 2023

Figure S1: Significant concordance between silence of Hippo signature and YAP1 expression in human hepatocellular carcinoma (HCC); Figure S2: Venn diagram of gene lists from two different gene expression signatures; Table S1: Genes in the SOH signature; Table S2: Functional categories of genes in the SOH signature; Table S3: Canonical Pathways enriched in the SOH signature; Table S4: Significant association between the SOH subtype and YAP1 protein expression in HCC; Table S5: Univariate and multivariate Cox regression analyses of recurrence-free survival with continuous SOH probability; Table S6: Univariate and multivariate Cox regression analyses of overall survival; Table S7: Univariate and multivariate Cox regression analyses of overall survival with continuous SOH probability; Table S8: Drop in concordance index in multivariable analysis; Table S9: Concordance of silence of Hippo signature with other prognostic HCC gene expression signatures in the NCI cohort; Table S10: Characteristics of HCC patients in the MSH cohort, stratified by SOH signature.
Supplemental Table 4 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Table 4. Univariate analysis with respect to outcome in the transplantation group
Supplemental Table 3 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Table 3. Univariate analysis with respect to outcome in the resection group
Supplemental Figure Legends from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Figure Legends. The description of the Supplemental Figure 1-3
Supplemental Figure 1 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Figure 1. The human HCC cell lines that expressed EGFP under the control of the human K19 promoter
Supplemental Figure 4 from Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers
Authors: Boufraqech Myriem , Zhang Lisa , Nilubol Naris , Sadowski Samira M. , Kotian Shweta , Quezado Martha , Kebebew Electron
Published: April 2023

Cellular invasion and migration in cells transfected with siC or siTIMP4
Supplemental Figure 1 from Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers
Authors: Boufraqech Myriem , Zhang Lisa , Nilubol Naris , Sadowski Samira M. , Kotian Shweta , Quezado Martha , Kebebew Electron
Published: April 2023

SNAI2 promoter mutation decreased the reporter activity
Supplementary Tables S1-2 from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Authors: Jacobsen Helle J. , Poulsen Thomas T. , Dahlman Anna , Kjær Ida , Koefoed Klaus , Sen Jette W. , Weilguny Dietmar , Bjerregaard Bolette , Andersen Christina R. , Horak Ivan D. , Pedersen Mikkel W. , Kragh Michael , Lantto Johan
Published: April 2023

Supplementary Tables S1-2. Table S1 - Source, origin, subtype and growth medium for each cell line. Table S2 - Characteristics of tested patient-derived xenograft models.
Supplementary Figures S1-8 from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Authors: Jacobsen Helle J. , Poulsen Thomas T. , Dahlman Anna , Kjær Ida , Koefoed Klaus , Sen Jette W. , Weilguny Dietmar , Bjerregaard Bolette , Andersen Christina R. , Horak Ivan D. , Pedersen Mikkel W. , Kragh Michael , Lantto Johan
Published: April 2023

Supplementary Figures S1-8. Figure S1 - Analysis of nonlinear blending synergy for the pairs of antibodies that constitute Pan-HER. Figure S2 - In vitro comparison of Pan-HER and a combination of cetuximab, trastuzumab and MM-121. Figure S3 - In vivo assessment of nonlinear blending synergy for the target specificities in the Pan-HER mixture. Figure S4 - Dose titration of Pan-HER in the BxPC3 xenograft model. Figure S5 - IHC analysis of Calu-3 tumors. Figure S6 - Assessment of cell death and cell cycle arrest. Figure S7 - Assessment of ADCC in a panel of cell lines. Figure S8 - Analysis of the effect of receptor internalization on effector functions.
supplementary table and figures from Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study
Authors: Wang Yu , Liu Qi-Fa , Xu Lan-Ping , Liu Kai-Yan , Zhang Xiao-Hui , Ma Xiao , Wu Mei-Qing , Wu De-Pei , Huang Xiao-Jun
Published: April 2023

Table S1. Results of univariate analysis of outcomes and contributing factors Figure S1: Influence of family relationship on overall survival after HID-HSCT Figure S2: Influence of HLA matching on overall survival after HID-HSCT
Supplementary Materials and Methods from miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer
Authors: Gururajan Murali , Josson Sajni , Chu Gina Chia-Yi , Lu Chia-Lun , Lu Yi-Tsung , Haga Christopher L. , Zhau Haiyen E. , Liu Chunyan , Lichterman Jake , Duan Peng , Posadas Edwin M. , Chung Leland W.K.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure 7 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Schematic showing the underlying mechanism of KITENIN/ErbB4-CYT-2 in colon tumor progression.
Supplemental Table and Figure Legends from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Table Legends and Supplemental Figure Legends
Supplemental Table 2 from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Table 2. Identification of BCL2 translocation events
Supplementary Figure 4 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Generation and characterization of villin-KITENIN/APCmin/+ mice.
Supplemental Figure 3 from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Figure 3. COO correlations across platforms
Supplementary Figure S2. from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure S2. ROC curves for OS17 recurrence vs. average soft-tissue margin length.
Table S2 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Table S2. Antibodies used for the IHC and IF studies. Antibodies and conditions used for the IHC and IF studies
Supplementary Table 3 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Table 3. MPFC analysis of total AML bone marrow sample according to FLT3 mutational status.
Supplementary Table 2 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Table 2. Characteristics of the AML patients according to FLT3 and NPM1 gene mutational status.
Supplemental Table 1 Holkova 8631 from A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Authors: Holkova Beata , Zingone Adriana , Kmieciak Maciej , Bose Prithviraj , Badros Ashraf Z. , Voorhees Peter M. , Baz Rachid , Korde Neha , Lin Hui-Yi , Chen Jin-Qiu , Herrmann Michelle , Xi Liqiang , Raffeld Mark , Zhao Xiuhua , Wan Wen , Tombes Mary Beth , Shrader Ellen , Weir-Wiggins Caryn , Sankala Heidi , Hogan Kevin T. , Doyle Austin , Annunziata Christina M. , Wellons Martha , Roberts John D. , Sullivan Daniel , Landgren Ola , Grant Steven
Published: April 2023

Supplementary Table S1. RAS/BRAF mutation status
Supplementary Tables 1 - 2 from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Authors: Nakaoku Takashi , Tsuta Koji , Ichikawa Hitoshi , Shiraishi Kouya , Sakamoto Hiromi , Enari Masato , Furuta Koh , Shimada Yoko , Ogiwara Hideaki , Watanabe Shun-ichi , Nokihara Hiroshi , Yasuda Kazuki , Hiramoto Masaki , Nammo Takao , Ishigame Teruhide , Schetter Aaron J. , Okayama Hirokazu , Harris Curtis C. , Kim Young Hak , Mishima Michiaki , Yokota Jun , Yoshida Teruhiko , Kohno Takashi
Published: April 2023

XLSX file - 22KB, Supplementary Table S1. RNA sequencing of 32 IMAs. Supplementary Table S2. PCR Primers used for RT-PCR screening.
Figure S5 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Authors: Madore Jason , Strbenac Dario , Vilain Ricardo , Menzies Alexander M. , Yang Jeen Y. H. , Thompson John F. , Long Georgina V. , Mann Graham J. , Scolyer Richard A. , Wilmott James S.
Published: April 2023

Meta-analysis of TCGA classification clusters. A) Methylation classification clusters, and B) Mutation classification clusters, described by the cancer genome atlas network. The hypomethylated cluster is associated with PD-L1 positive status (p = 0.047; Fishers exact test). No significant correlations were found for mutation clusters, although the NF1 mutant cluster was restricted to PD-L1 positive tumors (p = 0.096; Fishers exact test).
Supplementary Table Legends from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Authors: Nakaoku Takashi , Tsuta Koji , Ichikawa Hitoshi , Shiraishi Kouya , Sakamoto Hiromi , Enari Masato , Furuta Koh , Shimada Yoko , Ogiwara Hideaki , Watanabe Shun-ichi , Nokihara Hiroshi , Yasuda Kazuki , Hiramoto Masaki , Nammo Takao , Ishigame Teruhide , Schetter Aaron J. , Okayama Hirokazu , Harris Curtis C. , Kim Young Hak , Mishima Michiaki , Yokota Jun , Yoshida Teruhiko , Kohno Takashi
Published: April 2023

PDF file - 41KB
Supplemental Tables 1-4 from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
Authors: Smith David C. , Eisenberg Peter D. , Manikhas Georgy , Chugh Rashmi , Gubens Matthew A. , Stagg Robert J. , Kapoun Ann M. , Xu Lu , Dupont Jakob , Sikic Branimir
Published: April 2023

Supplemental Tables 1-4. Supplemental Table 1: Treatment Emergent Adverse Events By Cohort (All Grades) Reported by >15% of Patients Supplemental Table 2: Pharmacokinetic NCA Parameters by Cohort Supplemental Table 3: Compartmental PK Analysis Final Parameter Estimates and Estimation Statistics Supplemental Table 4: RECIST Best Overall Tumor Response
supplemental figure legend from In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging
Authors: Zegers Catharina M.L. , van Elmpt Wouter , Reymen Bart , Even Aniek J.G. , Troost Esther G.C. , Öllers Michel C. , Hoebers Frank J.P. , Houben Ruud M.A. , Eriksson Jonas , Windhorst Albert D. , Mottaghy Felix M. , De Ruysscher Dirk , Lambin Philippe
Published: April 2023

Supplemental Figure Legend
Supplementary Tables S1-S3 from In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/CT Imaging
Authors: Zegers Catharina M.L. , van Elmpt Wouter , Reymen Bart , Even Aniek J.G. , Troost Esther G.C. , Öllers Michel C. , Hoebers Frank J.P. , Houben Ruud M.A. , Eriksson Jonas , Windhorst Albert D. , Mottaghy Felix M. , De Ruysscher Dirk , Lambin Philippe
Published: April 2023

Supplementary Tables S1-S3. Supplementary Table S1: Patient characteristics. Supplementary Table S2 Pearson's correlation coefficient (R) and corresponding p-values of GTVln based parameters on FDG Supplementary Table S3: Average distribution (mean+SD) of high (+) and low (-), HX4 and FDG uptake within the primary GTV.
Supplementary Figures legends from Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Authors: Ota Keiichi , Azuma Koichi , Kawahara Akihiko , Hattori Satoshi , Iwama Eiji , Tanizaki Junko , Harada Taishi , Matsumoto Koichiro , Takayama Koichi , Takamori Shinzo , Kage Masayoshi , Hoshino Tomoaki , Nakanishi Yoichi , Okamoto Isamu
Published: April 2023

Supplementary Figures legends. Supplementary Figures legends
Supplementary Table 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Authors: Azad Arun A. , Volik Stanislav V. , Wyatt Alexander W. , Haegert Anne , Le Bihan Stephane , Bell Robert H. , Anderson Shawn A. , McConeghy Brian , Shukin Robert , Bazov Jenny , Youngren Jack , Paris Pamela , Thomas George , Small Eric J. , Wang Yuzhuo , Gleave Martin E. , Collins Colin C. , Chi Kim N.
Published: April 2023

Supplementary Table 1. Genome copy number calls for all patients.
Supplementary figure 1 from The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer
Authors: Lennartz Maximilian , Minner Sarah , Brasch Sophie , Wittmann Hilko , Paterna Leonard , Angermeier Katja , Öztürk Eray , Shihada Rami , Ruge Mingu , Kluth Martina , Koop Christina , Wilczak Waldemar , Krech Till , Lebok Patrick , Wittmer Corinna , Heinzer Hans , Steuber Thomas , Adam Meike , Huland Hartwig , Graefen Markus , Haese Alexander , Simon Ronald , Sauter Guido , Schlomm Thorsten
Published: April 2023

Benefit of the 3-level DNA score beyond the CAPRA-S nomogram for prediction of early biochemical recurrence. A) Prognostic impact of different levels of the CAPRA-S score. B)-F) Additional prognostic impact of the 3-level DNA score in subsets of cancers with B) CAPRA-S score 0-1, C) CAPRA-S score 2-3, D) CAPRA-S score 4-5, E) CAPRA-S score 6-8, F) CAPRA-S score 9-12. The 3-level DNA score combines cancers according to the following criteria: negative, DNA diploid and no deletion; intermediate, DNA diploid with deletion (of at least one of PTEN and 6q) or DNA tetraploid without deletion; high, DNA tetraploid with deletion or DNA aneuploidy.
Supplementary Table S1 from Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker
Authors: Iasonos Alexia , Chapman Paul B. , Satagopan Jaya M.
Published: April 2023

NSABP trial breast data on 3-year disease free survival
Supplemental Table 2 from Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer
Authors: Li Jian , Ye Changkun , Mansmann Ulrich R.
Published: April 2023

Downregulation of MSM components based on erlotinib treatment
Supplemental Table 1 from Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer
Authors: Li Jian , Ye Changkun , Mansmann Ulrich R.
Published: April 2023

Downregulation of MSM components based on cetuximab treatment
Supplementary methods from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary methods. These are more detailed methods than can be included in the body of the article.
Supplementary Figure 1 from Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia
Authors: Yamada Atsushi , Horimatsu Takahiro , Okugawa Yoshinaga , Nishida Naoshi , Honjo Hajime , Ida Hiroshi , Kou Tadayuki , Kusaka Toshihiro , Sasaki Yu , Yagi Makato , Higurashi Takuma , Yukawa Norio , Amanuma Yusuke , Kikuchi Osamu , Muto Manabu , Ueno Yoshiyuki , Nakajima Atsushi , Chiba Tsutomu , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary figure 1: Expression levels of serum miR-21, miR-29a and miR-125b in healthy controls (HC) vs. patients with colorectal neoplasms (CRN), after exclusion of 8 patients with colorectal cancer.
Supplementary Figure S3 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary Figure S3. Treatment regimens for each patient, with relapse designated day 0.
Supplementary Figure S2 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary Figure S2. Consort flow diagram.
Supplemental Figure Legends from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
Authors: Karjalainen Katja , Jaalouk Diana E. , Bueso-Ramos Carlos , Bover Laura , Sun Yan , Kuniyasu Akihiko , Driessen Wouter H.P. , Cardó-Vila Marina , Rietz Cecilia , Zurita Amado J. , O'Brien Susan , Kantarjian Hagop M. , Cortes Jorge E. , Calin George A. , Koivunen Erkki , Arap Wadih , Pasqualini Renata
Published: April 2023

Supplemental Figure Legends
Supplementary Figure S1 from Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Authors: Brown Christine E. , Badie Behnam , Barish Michael E. , Weng Lihong , Ostberg Julie R. , Chang Wen-Chung , Naranjo Araceli , Starr Renate , Wagner Jamie , Wright Christine , Zhai Yubo , Bading James R. , Ressler Julie A. , Portnow Jana , D'Apuzzo Massimo , Forman Stephen J. , Jensen Michael C.
Published: April 2023

Supplementary Figure S1. Catheter position with respect to resection site.
Supplementary Table S1 from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Authors: Tateishi Kensuke , Iafrate A. John , Ho Quan , Curry William T. , Batchelor Tracy T. , Flaherty Keith T. , Onozato Maristela L. , Lelic Nina , Sundaram Sudhandra , Cahill Daniel P. , Chi Andrew S. , Wakimoto Hiroaki
Published: April 2023

Supplemental Table S1 Putative Metabolites
Supplementary Figures from Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Authors: Tateishi Kensuke , Iafrate A. John , Ho Quan , Curry William T. , Batchelor Tracy T. , Flaherty Keith T. , Onozato Maristela L. , Lelic Nina , Sundaram Sudhandra , Cahill Daniel P. , Chi Andrew S. , Wakimoto Hiroaki
Published: April 2023

Supplementary Figure S1. Nampt inhibitor effects in glioblastoma tumorsphere cells. Supplementary Figure S2. Characterization of Nampt inhibitor effects in MYC/MYCN driven glioblastoma cells. Supplementary Figure S3. Characterization of NAD+-synthesis pathways in glioblastoma cells. Supplementary Figure S4. Nampt inhibitors induce apoptosis and disrupt intracellular metabolism pathways in MYC/MYCN amplified glioblastoma cells. Supplementary Figure S5. Fluorescent in situ hybridization (FISH) for MYC and MYCN in standard cancer cell lines. Supplementary Figure S6. Effect of Nampt inhibitors in Myc-driven standard cancer cell lines. Supplementary Figure S7. In vivo efficacy of Nampt inhibitor in MYC amplified H1975 xenografts. Supplementary Figure S8. NAMPT inhibitors were well tolerated in SCID mice bearing flank or orthotopic xenografts.
Supplementary Figure 2 from Gain of HIF-1α under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes
Authors: Lee Young-Ho , Bae Hyun Cheol , Noh Kyung Hee , Song Kwon-Ho , Ye Sang-kyu , Mao Chih-Ping , Lee Kyung-Mi , Wu T.-C. , Kim Tae Woo
Published: April 2023

Supplementary Figure 2. Immune selection induces HIF-1α in CaSki human cancer cell.
Supplementary Figure 1 from Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
Authors: Doshi Sameer , Gisleskog Per Olsson , Zhang Yilong , Zhu Min , Oliner Kelly S. , Loh Elwyn , Ruixo Juan Jose Perez
Published: April 2023

Supplementary Figure 1. Goodness-of-Fit Plots for the Pharmacokinetic Model
Table and Figure legends for Supplementary data from Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Authors: Klintman Marie , Buus Richard , Cheang Maggie Chon U. , Sheri Amna , Smith Ian E. , Dowsett Mitch
Published: April 2023

Table and Figure legends for Supplementary data
Supplementary Figure S5 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Figure S5. Density of MRC positive macrophages is not dependent on tumor size and tumor cells are able to induce Clever-1 expression.
Supplementary Figure S3 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Figure S3. Clever-1 is present in rabbit lymphatics but the lymphoma cell line KCA used in the homing experiments lacks its expression.
Supplementary Table S2. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Table S2. Mutations shared between tumor foci in blocks Q and S.
Supplementary Table S1. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Table S1. AR T878A Mutations in genomic DNA from CRPC patients failing abiraterone or ketoconazole.
Supplementary Figure S1 from Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis
Authors: Karikoski Marika , Marttila-Ichihara Fumiko , Elima Kati , Rantakari Pia , Hollmén Maija , Kelkka Tiina , Gerke Heidi , Huovinen Ville , Irjala Heikki , Holmdahl Rikard , Salmi Marko , Jalkanen Sirpa
Published: April 2023

Supplementary Figure S1. Clever-1 positive macrophages are not present in lymph nodes undergoing immune response
Supplementary Figure S1. from Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Authors: Chen Eddy J. , Sowalsky Adam G. , Gao Shuai , Cai Changmeng , Voznesensky Olga , Schaefer Rachel , Loda Massimo , True Lawrence D. , Ye Huihui , Troncoso Patricia , Lis Rosina L. , Kantoff Philip W. , Montgomery Robert B. , Nelson Peter S. , Bubley Glenn J. , Balk Steven P. , Taplin Mary-Ellen
Published: April 2023

Supplementary Figure S1. Histology and PIN-4 immunohistochemistry on tumor foci in blocks Q and S.
Figure S4 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Figure S4. FGFR1 dependency in 584-A2 and CCL30 cells assessed by RNAi-mediated FGFR1 silencing.
Figure S2 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
Authors: Göke Friederike , Franzen Alina , Hinz Trista K. , Marek Lindsay A. , Yoon Petros , Sharma Rakesh , Bode Maike , von Maessenhausen Anne , Lankat-Buttgereit Brigitte , Göke Antonia , Golletz Carsten , Kirsten Robert , Boehm Diana , Vogel Wenzel , Kleczko Emily K. , Eagles Justin R. , Hirsch Fred R. , Van Bremen Tobias , Bootz Friedrich , Schroeck Andreas , Kim Jihye , Tan Aik-Choon , Jimeno Antonio , Heasley Lynn E. , Perner Sven
Published: April 2023

Figure S2. Effect of BGJ398 on Ki67 staining, cleaved caspase 3 levels and phospho-ERK levels in HNSCC cell lines.
Supplementary Figure S2 from Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Authors: Bonito Nair A. , Borley Jane , Wilhelm-Benartzi Charlotte S. , Ghaem-Maghami Sadaf , Brown Robert
Published: April 2023

Individual CpG site DNA methylation (beta values) grouped by RECIST chemotherapy response in HH cohort.
Supplementary Figure S1 from Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Authors: Bonito Nair A. , Borley Jane , Wilhelm-Benartzi Charlotte S. , Ghaem-Maghami Sadaf , Brown Robert
Published: April 2023

Flow of patients
SUPPLEMENTARY DATA from PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Authors: Sabbatino Francesco , Villani Vincenzo , Yearley Jennifer H. , Deshpande Vikram , Cai Lei , Konstantinidis Ioannis T. , Moon Christina , Nota Sjoerd , Wang Yangyang , Al-Sukaini Ahmad , Zhu Andrew X. , Goyal Lipika , Ting David T. , Bardeesy Nabeel , Hong Theodore S. , Fernandez-del Castillo Carlos , Tanabe Kenneth K. , Lillemoe Keith D. , Ferrone Soldano , Ferrone Cristina R.
Published: April 2023

Figure S2. Representative staining patterns of formalin-fixed, paraffinembedded primary ICC lesions with HLA-DR, DQ and DP β chain-specific mAb LGII- 612.14.
Supplementary Figure 4 from Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression
Authors: Lee Jiyoon , Condello Salvatore , Yakubov Bakhtiyor , Emerson Robert , Caperell-Grant Andrea , Hitomi Kiyotaka , Xie Jingwu , Matei Daniela
Published: April 2023

Supplementary Figure 4. In situ enzymatic activity of TG2.
Supplementary Figure 3. from Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Authors: Henssen Anton , Althoff Kristina , Odersky Andrea , Beckers Anneleen , Koche Richard , Speleman Frank , Schäfers Simon , Bell Emma , Nortmeyer Maike , Westermann Frank , De Preter Katleen , Florin Alexandra , Heukamp Lukas , Spruessel Annika , Astrahanseff Kathy , Lindner Sven , Sadowski Natalie , Schramm Alexander , Astorgues-Xerri Lucile , Riveiro Maria E. , Eggert Angelika , Cvitkovic Esteban , Schulte Johannes H.
Published: April 2023

Mechanisms of reduced cell viability induced by OTX015 are cell line dependent. OTX015 reduces cell proliferation over time and induces cell cycle changes as well as apoptosis. (a) Representative photomicrographs of neuroblastoma cell lines treated with OTX015 for 72 h. Scale bar=200 µm. (b) The slope (1/h) of cell proliferation over time measured using xCELLigence of cell lines treated with OTX015. Significance was measured with the Student's t test. (c) Cell proliferation monitored using the xCELLigence system over time in neuroblastoma cell lines treated with 500 nM OTX015 (black) or DMSO control (grey). (d) Cell lines were treated 72 h with 500 nM OTX015 or DMSO, then fixed and stained with propidium iodide for flow cytometry. The distribution of OTX015-treated cells in different stages of the cell cycle is shown. (e) Fraction of apoptotic cells measured in the cell death ELISA assay after 72 h treatment with 250 nM or 500 nM OTX015 or DMSO control. Significant differences between treated cells versus controls were calculated by Student's t test. * p < 0.05, ** p < 0.01. (f) Cell proliferation measured in the BrdU ELISA after 72 h of treatment with 250 nM or 500 nM OTX015 or DMSO. Significant differences between treatment groups and the controls were calculated by Student's t test.
Supplementary Figure 5 from Dual HER2 Targeting Impedes Growth of HER2 Gene–Amplified Uterine Serous Carcinoma Xenografts
Authors: Groeneweg Jolijn W. , Hernandez Silvia F. , Byron Virginia F. , DiGloria Celeste M. , Lopez Hector , Scialabba Vanessa , Kim Minji , Zhang Ling , Borger Darrell R. , Tambouret Rosemary , Foster Rosemary , Rueda Bo R. , Growdon Whitfield B.
Published: April 2023

Supplementary Figure 5. HER2 inhibition in mice harboring non-HER2 amplified SPEC2 (A) or EnCa2 (B) xenografts did not affect tumor cell apoptosis, as shown by TUNEL analysis. Representative images of TUNEL (green) and DAPI (blue) stained sections of the differently treated xenografts are shown. Scale bars: 50 Ã‚Âµm.
Supplementary Table 1, Supplementary Figures 1-7 from InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Authors: Ma Yufang , Tang Nan , Thompson Reid C. , Mobley Bret C. , Clark Steven W. , Sarkaria Jann N. , Wang Jialiang
Published: April 2023

Supplementary Table 1. EGFR and PTEN mutational status in glioblastoma samples; Supplementary Figure 1. Expression of EGFR in glioblastoma cells cultured in serum-free medium; Supplemental Figure 2. Insulin, IGF1, and PDGF-AB confers resistance to gefitinib; Supplemental Figure 3. Inhibition of InsR/IGF1R improves response to EGFR inhibitors in Glioblastoma; Supplemental Figure 4. (A) GBM46 cells were starved overnight and stimulated with100 ng/ml insulin, IGF1 or EGF for 30 minutes in the presence of absence of 1 ô€ˆ�M gefitinib. (B) GBM12 and (C) GBM46 were treated with gefitinib {plus minus} OSI-906 for 24 hours and collected for immunoblotting; Supplemental Figure 5. (A) GBM12 GBM39 were infected with control lentivirus or lentivirus directing expression of Myr-AKT1 and selected with puromycin for 2 days; Supplemental Figure 6. Inhibition of the PI3K/AKT pathway sensitizes glioblastoma cells to EGFR Inhibitors; Supplemental Figure 7. (A) PC9 cells were treated with gefitinib {plus minus} OSI-906 and cellular response was determined as described in Fig. 2A; Supplemental Figure 8. (A) Animals bearing GBM76 and (B) GBM39 subcutaneous tumors were treated as described in Fig. 4 and methods. Median animal weights throughout the course of treatment were presented.